United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium topical suspension usp, 10% (lotion) is indicated in the topical treatment of acne vulgaris . sulfacetamide sodium topical suspension usp, 10% (lotion) is contraindicated for use by patients having known hypersensitivity to sulfonamides or any other component of this preparation (see warnings section).

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e) - nystatin cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by candida albicans and other susceptible candida species. this cream is not indicated for systemic, oral, intravaginal or ophthalmic use. nystatin cream is contraindicated in patients with a history of hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - ammonium lactate (unii: 67m901l9nq) (lactic acid, unspecified form - unii:33x04xa5at) - ammonium lactate lotion is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. ammonium lactate lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - metronidazole gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea. metronidazole gel, 1% is contraindicated in patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation. teratogenic effects: pregnancy category b. there are no adequate and well-controlled studies with the use of metronidazole gel in pregnant women. metronidazole crosses the placental barrier and enters the fetal circulation rapidly. no fetotoxicity was observed after oral administration of metronidazole in rats or mice at 200 and 20 times, respectively, the expected clinical dose. however, oral metronidazole has shown carcinogenic activity in rodents. because animal reproduction studies are not always predictive of human response, metronidazole gel should be used during pregnancy only if clearly needed. after oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. even though blood levels taken after topi

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - terconazole (unii: 0kj2ve664u) (terconazole - unii:0kj2ve664u) - terconazole vaginal suppositories, 80 mg is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). as this product is effective only for vulvovaginitis caused by the genus candida , the diagnosis should be confirmed by koh smears and/or cultures. patients known to be hypersensitive to terconazole or to any of the components of the suppositories.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - econazole nitrate (unii: h438wyn10e) (econazole - unii:6z1y2v4a7m) - econazole nitrate cream is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by trichophyton rubrum, trichophyton mentagrophytes, trichophyton tonsurans, microsporum canis, microsporum audouini, microsporum gypseum, and epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. econazole nitrate cream is contraindicated in individuals who have shown hypersensitivity to any of its ingredients.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate topical solution is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 ml/week because of the potential for the drug to suppress the hpa axis. this product is not recommended for use in pediatric patients under 12 years of age. clobetasol propionate topical solution is contraindicated in patients with primary infections of the scalp, or in patients who are hypersensitive to clobetasol propionate, other corticosteroids, or any ingredient in this preparation.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene gel is indicated for the topical treatment of acne vulgaris. adapalene gel should not be administered to individuals who are hypersensitive to adapalene or any of the components in the vehicle gel.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate cream, 0.05% (emollient) is a super-high potency corticosteroid indicated for: clobetasol propionate cream, 0.05% (emollient) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age and older. treatment should be limited to 2 consecutive weeks, and the total dosage should not exceed 50 grams per week. clobetasol propionate cream, 0.05% (emollient) is indicated for the topical treatment of moderate to severe plaque-type psoriasis. treatment beyond 4 consecutive weeks is not recommended. use in pediatric patients under 16 years of age is not recommended. clobetasol propionate cream, 0.05% (emollient) should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. the total dosage should not exceed 50 grams per week. avoid use if skin atrophy is present at the treatment site. none there are no adequate and well-controlled studies in pregnant w